In this downloadable slideset, M. Dror Michaelson, MD, PhD, explores the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating renal cell carcinoma.
In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating advanced urothelial cell carcinoma.
In this downloadable slideset, Sumanta Kumar Pal, MD, addresses the management of adverse events associated with immune checkpoint inhibitors for optimal outcomes in patients with advanced urothelial cell and renal cell carcinoma.
Download this pocket guide for information on dosing, administration, and clinical management for the current FDA-approved checkpoint inhibitor, nivolumab, in advanced RCC. This pdf includes a checklist for assessing your patients for common immune-related adverse events in the clinic.
Download this a comprehensive pocket guide with dosing and administration information for currently FDA-approved checkpoint inhibitors in urothelial carcinoma. This guide also includes a checklist for detecting common immune-related adverse events in your patients receiving these agents.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.